Identification of the direct involvement of PPAR-γ in the mechanism of action of mesalazine, a clinically effective drug often used to treat ulcerative colitis, has highlighted the anti-inflammatory role of PPAR-γ and renewed the search for novel PPAR-γ agonists to treat IBD [9]. The gene discussed is PPARG; the disease is inflammatory bowel disease.